Skip to main navigation
Skip to search
Skip to main content
University College Cork Home
Home
Profiles
Research units
Research output
Activities
Prizes
Datasets
Impacts
Courses
Press/Media
Search by expertise, name or affiliation
Anti-TNF therapy in Crohn's disease
S. Ghosh
Imperial College Healthcare NHS Trust
Research output
:
Chapter in Book/Report/Conference proceedings
›
Chapter
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Anti-TNF therapy in Crohn's disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
100%
Tumor Necrosis
100%
Infliximab
100%
Immunosuppressive Agent
50%
Diseases
25%
Receptor
12%
Ulcerative Colitis
12%
Chimeric Protein
12%
Adalimumab
12%
Etanercept
12%
Tumor Necrosis Factor Antibody
12%
Certolizumab Pegol
12%
Onercept
12%
Immunology and Microbiology
Tumor Necrosis Factor Alpha
100%
Crohn's Disease
100%
Infliximab
100%
Immunosuppressive Therapy
50%
Ulcerative Colitis
12%
Adalimumab
12%
Certolizumab Pegol
12%
Tumor Necrosis Factor Antibody
12%
Etanercept
12%